Arrowhead, Takeda liver drug headed to PhIII despite placebo response's dent on stock

Paul Schloesser

Associate Editor

Arrowhead Pharmaceuticals reported Monday that its Takeda-partnered program reduced liver scarring and mutant protein levels in patients with alpha-1 antitrypsin deficiency, a rare liver disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arrowhead, Takeda liver drug headed to PhIII despite placebo response's dent on stock

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ar­row­head, Take­da liv­er drug head­ed to PhI­II de­spite place­bo re­spon­se's dent on stock

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Arrowhead, Takeda liver drug headed to PhIII despite placebo response's dent on stock